FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office Of								Serial No. 09/522,117
	(Use	several sheets if	necessary)	A FRANCISCO				
Applicants:							vell et al.	
					Filing Date March 9, 20	000		Group 1624
	-		U. S	S. PATENT DO	CUMENTS			
Examiner Initial		Document Number	Date	Name		Class	Subclass	Filing Date if Appropriate
								
·						-		
			FUBE	 GN PATENT I	OCUMENTS	1	<u>.</u>	<u> </u>
		Document		untry	Class	Subclass	Translation Yes No	
		` `						
							- A	*
		OTHER DOO	CUMENTS (I	ncluding Author	, Title, Date, P	ertinent Pages	, Etc.)	
VD	1.	S. Arneric & M. Williams, "Nicotinic Agonists in Alzheimer's Disease: Does the Molecular Diversity of Nicotine Receptors Offer the Opportunity for Developing CNS-Selective Cholinergic Channel Activators?" Int. Acad. Biomed. Drug Res., 7: 58-70 (1994).						
8	2.	Bencherif et al., "Metanicotine: A Nicotinic Agonist with CNS Selectivity - In Vitro Characterization," Society for Neuroscience Abstracts, 21(1-3): 605 (1995).						
V	3.	Perry et al., "Alteration in Nicotine Binding Sites in Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease: Possible Index of Early Neuropathology," <i>Elsevier Science Ltd.</i> , 64(2): 385-395 (1995).						
19	4.	B. Sahakian & J. Coull, "Nicotine and Tetrahydroaminoacradine: Evidence for Improved Attention in Patients with Dementia of the Alzheimer Type," <i>Drug Development Research</i> , 31: 80-88 (1994).						
V)	5.	Wilson Jr. et al., "Nicotine-Like Actions of cis-Metanicotine and trans-Metanicotine," The Journal of Pharmacology and Experimental Therapeutics, 196(3): 685-696 (1976).						
	6	Supplementary Partial European Scarch Report; Date of completion: July 11, 2001.						

EXAMINER Valuation of the second of this form with next communication to applicate the second of the